Hepatitis C treatment in patients with kidney disease

Kidney International

Volumn 84, Issue 5, 2013, Pages 874-879

  Fabrizi, Fabrizio ^a   Aghemo, Alessio ^a   Messa, Piergiorgio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

dialysis; hepatitis C; interferon; ribavirin; survival

Indexed keywords

ALPHA2A INTERFERON; CREATININE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GLOMERULUS FILTRATION RATE; HAIR LOSS; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEPATITIS C; HUMAN; INFECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MENTAL DISEASE; MONOTHERAPY; PATIENT CARE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; COMORBIDITY; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888326640     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.264     Document Type: Short Survey

References (56)

1. Pol S, Vallet-Pichard A, Corouge M et al. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contrib Nephrol 2012; 176: 1-9.
2. Jadoul M, Barril G. Hepatitis C in haemodialysis: epidemiology and prevention of hepatitis C virus transmission. Contrib Nephrol 2012; 176: 35-41.
3. Fissell R, Bragg-Gresham J, Woods J et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004; 65: 2335-2342.
4. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73(Suppl 109): S1-S99.
5. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality J Viral Hepat 2012; 19: 601-607.
6. Goodkin D, Bragg-Gresham J, Koenig G et al. Association of comorbid conditions and mortality in haemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes, and practice patterns. J Am Soc Nephrol 2003; 14: 3270-3277.
7. Oyake N, Shimada T, Murakami Y et al. Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol 2008; 21: 345-353.
8. Roth D, Gaynor J, Reddy K et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152-1160.
9. Cosio F, Sedmak D, Henry M et al. The high prevalence of severe early post-transplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-1059.
10. Cruzado J, Carrera M, Torras J et al. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178.
11. Morales J, Pascual-Capdevila J, Campistol J et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63: 1634-1639.
12. Roth D, Cirocco R, Zucker K et al. De novo membrano-proliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676-1682.
13. Bloom R, Rao V, Weng F et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374-1380.
14. Wolffenbuttel L, Poli D, Manfro R et al. Cyclosporine pharmacokinetics in anti-HCV positive patients. Clin Transplant 2004; 18: 654-660.
15. Forman J, Tolkoff-Rubin N, Pascual M et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004; 15: 3249-3255.
16. Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
17. Cruzado J, Casanovas Taltavull T, Torras J et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV RNA clearance. Am J Transplant 2003; 3: 357-360.
18. Gursoy M, Gunever N, Koksal R et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000; 32: 561-562.
19. Mahmoud I, Sovh M, El-Habashi A et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139.
20. Fabrizi F, Dixit V, Messa P et al. Interferon mono-therapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008; 15: 79-88.
21. Strader D, Wright T, Thomas D et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
22. Fried M, Shiffman M, Reddy K et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
23. Manns M, McHutchison J, Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
24. Hadziyannis S, Sette H, Morgan T et al. Pegasys International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
25. Rostaing L, Chatelut E, Payen J et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic haemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-2348.
26. Fabrizi F, Dixit V, Martin P et al. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2011; 18: e263-e269.
27. Rostaing L, Weclawiak H, Izopet J et al. Treatment of hepatitis C virus infection after kidney transplantation. Contrib Nephol 2012; 176: 87-96.
28. McHutchison JG, Everson GT, Gordon SC et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
29. Hezode C, Forestier N, Dusheiko G et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
30. Ghany G, Nelson D, Strader D et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
31. Pereira B, Natov S, Bouthot B et al. Effects of hepatitis C infection and renal transplantation on survival. Kidney Int 1998; 53: 1374-1381.
32. Stehman-Breen C, Emerson S, Gretch D et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-634.
33. Nakayama E, Akiba T, Marumo F et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
34. Espinosa M, Martin-Malo A, Alvarez de Lara M et al. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-74.
35. Di Napoli A, Pezzotti P, Di Lallo D et al. Lazio Dialysis Registry. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-37.
36. Kalantar-Zadeh K, Kilpatrick R, McAllister C et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593.
37. Wang S, Liu J, Chou C et al. Mortality in hepatitis C-positive patients treated with peritoneal dialysis. Perit Dial Int 2008; 28: 183-187.
38. Johnson D, Dent H, Yao Q et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24: 1598-1603.
39. Scott D, Wong J, Spicer T et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-1171.
40. Ohsawa M, Kato K, Tanno K et al. Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients. J Epidemiol 2011; 21: 491-499.
41. Peck-Radosavljevic M, Boletis J, Besisik F et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011; 9: 242-248.
42. Basic-Jukic N, Gulin M, Slavicek J et al. Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia. Kidney Blood Press Res 2011; 34: 53-57.
43. Akhan S, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 2008; 36: 341-344.
44. Ayaz C, Celen M, Yuce U et al. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008; 14: 255-259.
45. Sikole A, Dzekova P, Selja N et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Renal Fail 2007; 29: 961-966.
46. Espinosa M, Arenas M, Aumente M et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in haemodialysis patients. Clin Nephrol 2007; 6: 366-373.
47. Covic A, Maftei I, Mardare N et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large multicenter audit. J Nephrol 2006; 19: 794-801.
48. Russo M, Ghalib R, Sigal S et al. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-443.
49. Sporea I, Popescu A, Sirli R et al. Pegylated interferon alpha2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12: 4191-4194.
50. Rendina M, Schena A, Castellaneta N et al. The treatment of chronic hepatitis C with pegylated interferon alpha2a (40 kDa) plus ribavirin in hemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 764-768.
51. Carriero D, Fabrizi F, Uriel A et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low dose ribavirin. Int J Artif Organs 2008; 31: 295-302.
52. Van Leusen R, Adang R, de Vries R et al. Pegylated interferon alfa-2a (40 kDa) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008; 23: 721-725.
53. Hakim W, Sheikh S, Inayat I et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol 2009; 43: 477-481.
54. Liu C, Liang C, Liu C et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009; 58: 314-316.
55. Deltenre P, Moreno C, Tran A et al. Antiviral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther 2011; 34: 454-461.
56. Giguere A, Anas A, Nasser T et al. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience. Eur J Intern Med 2011; 22: 582-586.